Pharma back in the EU antitrust spotlight
This article was originally published in SRA
Yesterday's raids on the premises of several pharmaceutical companies show that the European competition authorities are serious about taking action against suspected anticompetitive behaviour in the EU generics market.
You may also be interested in...
The Belgian authorities are taking steps to reduce the consumption of benzodiazepine-containing medicines, and have also reiterated the risks associated with the increasing use of opioid medications.
The bedding-in period is ending for Europe’s one-year-old system for preventing the circulation of fake medicines, and the scheme is gearing up for a more fully operational stage.
EU and US regulators have opposing views when it comes to Merck's applications for a new indication and new dosing schedule for the company's successful PD-1 inhibitor Keytruda.